IPO registrations (S-1, F-1) · Registrants
ACCELERON PHARMA INC
- SEC CIK
- 1280600 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2013-08-07, last 2014-01-21; 2 initial registrations, 3 amendments
- Outcome
- Final prospectus filed 2013-09-19; declared effective 2013-09-18
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 128 SIDNEY STREET, Cambridge, MA 02139
- EDGAR entity type
- operating
- Insiders and CEO pay
- ACCELERON PHARMA INC on the corporate pages
Offering terms
- Proposed price range
- $13.00–$15.00 per share (S-1/A filed 2013-09-06)
- Final price
- $15.00 per share, within the range (424B4 filed 2013-09-19, an initial public offering)
- Shares sold
- 5,580,000
- Gross proceeds
- $83,700,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol XLRN
- Lead underwriters
- Citigroup; Leerink Partners
- Syndicate
- Piper Sandler; JMP Securities
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: ACCELERON PHARMA INC. Fuzzy (name and state)
- Form D issuer: ACCELERON PHARMA INC EXACT (CIK (EXACT))
- Lobbying client: ACCELERON PHARMA Fuzzy (name and state)
- Lobbying client: ACCELERON PHARMA INC Fuzzy (name and state)
- Lobbying client: ACCELERON PHARMA, INC Fuzzy (name and state)
- Lobbying registrant: ACCELERON PHARMA INC Fuzzy (name and state)
- SEC filer: ACCELERON PHARMA INC EXACT (CIK (EXACT))
Filings 11
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2013-08-07 | S-1 | S-1 (registration) | ACCELERON PHARMA INC | 0001047469-13-008148 ↗ |
| 2013-08-20 | S-1/A | S-1/A (amendment) | ACCELERON PHARMA INC | 0001047469-13-008540 ↗ |
| 2013-09-06 | S-1/A | S-1/A (amendment) | ACCELERON PHARMA INC | 0001047469-13-008888 ↗ |
| 2013-09-18 | S-1MEF | S-1MEF (added securities) | ACCELERON PHARMA INC | 0001047469-13-009153 ↗ |
| 2013-09-18 | EFFECT | EFFECT (declared effective) | ACCELERON PHARMA INC | 9999999995-13-002703 ↗ |
| 2013-09-19 | 424B4 | 424B4 (final prospectus) | ACCELERON PHARMA INC | 0001047469-13-009174 ↗ |
| 2014-01-09 | S-1 | S-1 (registration) | ACCELERON PHARMA INC | 0001047469-14-000098 ↗ |
| 2014-01-21 | S-1/A | S-1/A (amendment) | ACCELERON PHARMA INC | 0001047469-14-000238 ↗ |
| 2014-01-22 | S-1MEF | S-1MEF (added securities) | ACCELERON PHARMA INC | 0001047469-14-000290 ↗ |
| 2014-01-22 | EFFECT | EFFECT (declared effective) | ACCELERON PHARMA INC | 9999999995-14-000180 ↗ |
| 2014-01-23 | 424B4 | 424B4 (final prospectus) | ACCELERON PHARMA INC | 0001047469-14-000314 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2013-09-06 | S-1/A | registration statement | $13.00–$15.00 | $14.00 | 4,650,000 | $65,100,000 | Nasdaq XLRN | 4 | primary document; range, price sentence, shares headline, proceeds computed, cover names 4 | document ↗ |
| 2013-09-19 | 424B4 | final prospectus | $15.00 | 5,580,000 | $83,700,000 | Nasdaq XLRN | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Advanced Technology Ventures VII(B), L.P. | TenPercentOwner | 1 | 2013 | ||
| Advanced Technology Ventures VII(C), L.P. | TenPercentOwner | 1 | 2013 | ||
| ADVANCED TECHNOLOGY VENTURES VII LP | TenPercentOwner | 1 | 2013 | ||
| Advanced Technology Ventures VI, L.P. | TenPercentOwner | 1 | 2013 | ||
| AFEYAN NOUBAR | TenPercentOwner | 1 | 2013 | ||
| AGTC ADVISORS FUND LP | TenPercentOwner | 1 | 2013 | ||
| AGTC Partners, L.P. | TenPercentOwner | 1 | 2013 | ||
| Applied Genomic Technology Capital Fund LP | TenPercentOwner | 1 | 2013 | ||
| ATV Alliance 2003, L.P. | TenPercentOwner | 1 | 2013 | ||
| ATV Associates VII, L.L.C. | TenPercentOwner | 1 | 2013 | ||
| ATV Associates VI, L.L.C. | TenPercentOwner | 1 | 2013 | ||
| ATV Entrepreneurs VI, L.P. | TenPercentOwner | 1 | 2013 | ||
| CELGENE CORP /DE/ | TenPercentOwner | 9 | 2013–2020 | ||
| Ertel Steven D | Officer | EVP & Chief Operating Officer; SVP & Chief Business Officer | 33 | 2013–2017 | |
| EVNIN ANTHONY B | Director; Director,TenPercentOwner | 4 | 2013 | ||
| Flagship Ventures Management, Inc. | TenPercentOwner | 1 | 2013 | ||
| George Jean | Director | 19 | 2013–2020 | ||
| Golumbeski George | Director | 1 | 2013 | ||
| GORDON CARL L | Director | 1 | 2013 | ||
| ISALY SAMUEL D | Other; TenPercentOwner | 2 | 2013 | ||
| KANIA EDWIN M JR | Director | 10 | 2013–2015 | ||
| Knopf John L | Director,Officer | CEO and President | 30 | 2013–2016 | |
| Kumar Ravindra | Officer | SVP & Chief Scientific Officer; VP & Chief Scientific Officer | 40 | 2013–2019 | |
| Maniatis Tom | Director | 15 | 2013–2019 | ||
| MCGUIRE TERRANCE | Director | 21 | 2013–2017 | ||
| MCLAUGHLIN KEVIN F | Officer | SVP, CFO and Treasurer | 56 | 2013–2021 | |
| NewcoGen Group, Inc. | TenPercentOwner | 1 | 2013 | ||
| ORBIMED ADVISORS LLC | Other; TenPercentOwner | 2 | 2013 | ||
| ORBIMED CAPITAL GP II LLC | Other; TenPercentOwner | 2 | 2013 | ||
| Polaris Venture Management Co IV LLC | Other; TenPercentOwner | 5 | 2013–2014 | ||
| POLARIS VENTURE PARTNERS ENTREPRENEURS FUND IV LP | Other; TenPercentOwner | 5 | 2013–2014 | ||
| POLARIS VENTURE PARTNERS IV LP | Other; TenPercentOwner | 5 | 2013–2014 | ||
| POPS RICHARD F | Director | 9 | 2013–2019 | ||
| Quisel John D | Officer | EVP, CBO and Secretary; EVP, Chief Business Officer; SVP, Bus. Dev., GC & Secretary; SVP, Corp. Dev., GC & Sec.; SVP Gen. Counsel & Secretary; VP General Counsel & Secretary | 43 | 2013–2020 | |
| Sherman Matthew L | Officer | EVP & Chief Medical Officer; SVP & Chief Medical Officer | 47 | 2013–2018 | |
| Steininger Robert J II | Officer | SVP, Manufacturing | 1 | 2013 | |
| VEF Management IV, LLC | TenPercentOwner | 2 | 2013 | ||
| VENROCK ASSOCIATES IV L P | TenPercentOwner | 2 | 2013 | ||
| VENROCK ENTREPRENEURS FUND IV L P | TenPercentOwner | 2 | 2013 | ||
| Venrock Management IV, LLC | TenPercentOwner | 2 | 2013 | ||
| Venrock Partners, L.P. | TenPercentOwner | 2 | 2013 | ||
| Venrock Partners Management, LLC | TenPercentOwner | 2 | 2013 | ||
| Zakrzewski Joseph S | Director | 16 | 2013–2021 | ||
| ATV Entrepreneurs VII, L.P. | TenPercentOwner | 1 | 2013 | ||
| Kearney Terrence C | Director | 12 | 2014–2021 | ||
| Nader Francois | Director | 13 | 2014–2021 | ||
| MCCOURT Thomas A | Director | 10 | 2016–2021 | ||
| Dable Habib J | Director,Officer | CEO and President | 15 | 2016–2021 | |
| Rovaldi Christopher | Officer | SVP, Program Mgmt and Ops | 6 | 2017–2018 | |
| Smith Karen L. | Director | 9 | 2017–2021 | ||
| KANGO SUJAY | Officer | EVP, Chief Commercial Officer; SVP, Chief Commercial Officer | 15 | 2018–2021 | |
| Zeldin Robert K | Officer | EVP & Chief Medical Officer | 3 | 2018–2019 | |
| Veness Adam M | Officer | SVP, General Counsel and Sec.; VP, General Counsel and Sec. | 16 | 2019–2021 | |
| Backstrom Jay T. | Officer | EVP, Research and Development | 6 | 2019–2021 | |
| Malik Kemal | Director | 5 | 2020–2021 | ||
| Hite Christopher | Director | 4 | 2020–2021 | ||
| BRISTOL MYERS SQUIBB CO | TenPercentOwner | 3 | 2020 | ||
| Hamill Laura | Director | 4 | 2020–2021 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2012-01-04 | ACCELERON PHARMA INC | Biotechnology | $30,472,934 | $30,472,934 | 47 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | ACCELERON PHARMA INC. | MA | State business registries | name and state |
| Form D issuer | ACCELERON PHARMA INC | MA | Form D private offerings | CIK (EXACT) |
| Lobbying client | ACCELERON PHARMA | MA | Federal lobbying (LDA) | name and state |
| Lobbying client | ACCELERON PHARMA INC | MA | Federal lobbying (LDA) | name and state |
| Lobbying client | ACCELERON PHARMA, INC | MA | Federal lobbying (LDA) | name and state |
| Lobbying registrant | ACCELERON PHARMA INC | MA | Federal lobbying (LDA) | name and state |
| Paying company | Acceleron Pharma, Inc. | MA | Open Payments (drug and device company payments) | name and state |
| Patent assignee | Acceleron Pharma Inc. | MA | Patents (USPTO) | name and state |
| SEC filer | ACCELERON PHARMA INC | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Acceleron Pharma Inc. | MA | Trademarks (USPTO) | name and state |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), MA first:
- TRANSCEND THERAPEUTICS INC MA
- Eloxx Pharmaceuticals, Inc. MA
- PANACOS PHARMACEUTICALS, INC. MA
- CHARLES RIVER LABORATORIES INC MA
- AGENUS INC MA
- CURIS INC MA
- MOMENTA PHARMACEUTICALS INC MA
- bluebird bio, Inc. MA
- Altus Pharmaceuticals Inc. MA
- BioVex Group, Inc. MA
In other datasets, the same topic (Health) in MA:
- Nonprofit: ABBIE M GRIFFIN HOSPITAL FUND (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health